ADA Scientific Sessions 2025 Abstract

Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

By Nikolaj Klausholt Bak, Rachel Ga Yeon Lee, Angela Sinn,

Søren Snitker, Valdemar Uhre, Emily Cathrine Wenande,

Tine A. Bækdal

Trial in peopleInterventions

The paper

Nikolaj Klausholt Bak, Rachel Ga Yeon Lee, Angela Sinn,

Søren Snitker, Valdemar Uhre, Emily Cathrine Wenande,

Tine A. Bækdal

Søborg

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, late-breaking 1969-LB

doi.org/10.2337/db25-1969-lb

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes